IMNN
Imunon, Inc.Company Information
- Company Name
- Imunon, Inc.
- CIK
- CIK0000749647
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- IMNN: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- IMNN
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-08-20
- Last sale
- 2026-08-31
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 22,385
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 301,267
- Shares outstanding
- 5,232,625
- Ownership
- 5.76%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- -1.86%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 7 | 5 | 9 | 5 | 5 | 3 | 6 | 10 | 5 | 2 | 6 | 13 | ||||||
| Available For Sale Securities Debt Securities Current | - | - | - | - | - | - | - | - | - | 7 | 10 | 6 | ||||||
| Debt Securities Held To Maturity Accrued Interest After Allowance For Credit Loss | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Grants Receivable Current | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | ||||||
| Assets Current | 9 | 7 | 11 | 7 | 7 | 5 | 8 | 13 | 8 | 12 | 18 | 22 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Other Assets | ||||||||||||||||||
| Deferred Income Tax Assets Net | - | - | - | - | - | - | - | - | - | - | 1 | - | ||||||
| Restricted Cash | 5 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | ||||||
| Deposits Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 6 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 2 | ||||||
| Assets | 15 | 8 | 12 | 9 | 9 | 7 | 10 | 14 | 10 | 14 | 22 | 25 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Trade Current | 2 | 1 | 1 | 1 | 2 | 2 | 1 | 2 | 2 | 2 | 4 | 2 | ||||||
| Accrued Liabilities Current | 1 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 2 | 3 | 3 | ||||||
| Notes Payable Current | 2 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | ||||||
| Liabilities Current | 5 | 4 | 5 | 4 | 5 | 6 | 5 | 5 | 5 | 5 | 7 | 5 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Derivative Liabilities Noncurrent | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities | 11 | 5 | 5 | 5 | 6 | 6 | 5 | 6 | 6 | 6 | 9 | 7 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Additional Paid In Capital Preferred Stock | 2 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | - | 429 | 428 | 421 | 416 | 411 | 411 | 411 | 402 | 401 | 402 | 401 | ||||||
| Common Stocks Including Additional Paid In Capital | 430 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Retained Earnings Accumulated Deficit | -428 | -426 | -421 | -417 | -414 | -411 | -407 | -403 | -398 | -393 | -388 | -383 | ||||||
| Stockholders Equity Before Treasury Stock | 4 | 3 | 7 | 4 | 3 | 1 | 4 | 8 | 4 | 9 | 13 | 18 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | 0 | - | - | - | 0 | - | - | 0 | 0 | 0 | ||||||
| Treasury Stock Value | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Stockholders Equity | 4 | 3 | 7 | 4 | 3 | 0 | 4 | 8 | 4 | 8 | 13 | 18 | ||||||
| Liabilities And Stockholders Equity | 15 | 8 | 12 | 9 | 9 | 7 | 10 | 14 | 10 | 14 | 22 | 25 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 350 | 350 | 350 | 350 | 113 | 113 | 113 | 113 | 113 | 113 | 113 | 113 | ||||||
| Common Stock Shares Issued | 5 | 4 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Shares Outstanding | 5 | 4 | 3 | 3 | 32 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Treasury Stock Common Shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialImunon, Inc. (IMNN) — SEC Financial Statements & Analysis
Imunon, Inc. (IMNN) is a pharmaceutical preparations company, incorporated in DE. Imunon, Inc. trades on Nasdaq as: IMNN. Imunon, Inc. (IMNN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Imunon, Inc. carries a market cap of $9.31M, a P/E ratio of -0.63x, a P/B ratio of 2.22x, a P/S ratio of 63.96x, an enterprise value of $3.95M, and an EV/EBITDA multiple of -0.27x. On profitability, it posts an operating margin of -17591.64%, a net margin of -22287.62%, a Return on Equity (ROE) of -429.72%, a Return on Assets (ROA) of -123.77%, and a Return on Invested Capital (ROIC) of -142.93%. Per share, it reports EPS of $-2.81, diluted EPS of $-2.81, free cash flow per share of $-2.90, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -6.55% year-over-year, and EPS growth of -77.19% year-over-year. On the balance sheet, it maintains a current ratio of 1.82x, a quick ratio of 1.82x, working capital of $3.91M, a debt-to-equity ratio of 2.58x, a debt ratio of 0.72, an interest coverage ratio of -191.99x, free cash flow of $-15.18M (TTM), and net debt of $-5.36M. Figures sourced from SEC EDGAR.
- Market Cap
- $9.31M
- P/E TTM
- -0.63x
- EPS TTM
- $-2.81
- P/B TTM
- 2.22x
- ROE TTM
- -429.72%
- ROA TTM
- -123.77%
- Debt To Equity
- 2.58x
- Free Cash Flow TTM
- $-15.18M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Imunon, Inc. in?
Imunon, Inc. (IMNN) operates in the Pharmaceutical Preparations industry.
What exchange does IMNN trade on?
Imunon, Inc. (IMNN) trades on the Nasdaq.
Where is Imunon, Inc. incorporated?
Imunon, Inc. is incorporated in DE.
When was Imunon, Inc. (IMNN)'s most recent SEC filing?
Imunon, Inc. (IMNN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is IMNN's market cap?
Imunon, Inc. (IMNN) has a market capitalization of $9.31M as of 2026-06-30.
What is IMNN's EPS (earnings per share)?
Imunon, Inc. (IMNN)'s trailing twelve month EPS is $-2.81 as of 2026-06-30.
What is IMNN's ROE (return on equity)?
Imunon, Inc. (IMNN)'s trailing twelve month Return on Equity (ROE) is -429.72% as of 2026-06-30.
What is IMNN's ROA (return on assets)?
Imunon, Inc. (IMNN)'s trailing twelve month Return on Assets (ROA) is -123.77% as of 2026-06-30.
What is IMNN's ROIC (return on invested capital)?
Imunon, Inc. (IMNN)'s trailing twelve month Return on Invested Capital (ROIC) is -142.93% as of 2024-03-31.
What is IMNN's EV/EBITDA?
Imunon, Inc. (IMNN)'s trailing twelve month EV/EBITDA is -0.27x as of 2026-06-30.